BNTC - ベニテック・バイオファ―マ （Benitec Biopharma Limited） ベニテック・バイオファ―マBNTCのチャート
BNTCの企業情報
| symbol | BNTC |
|---|---|
| 会社名 | Benitec Biopharma Ltd （ベニテック・バイオファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- ベニテック・バイオファ―マはオ―ストラリアのバイオ医薬品企業。主に、特定遺伝子の発現を抑制するRNA干渉技術を用いて難病に対する治療法を開発する。遺伝病である眼球咽頭筋ジストロフィ―、またB型肝炎、肺がん、がん関連の神経障害性疼痛などの治療法に焦点を当てる。同社はC型肝炎、HIVやエイズの治療薬メ―カ―へ技術を提供する。本社はメルボルン。 benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options. |
| 本社所在地 | F6A/1-15 Barr Street Balmain Sydney New South Wales 2041 AUS |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | － |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2015年 |
| 従業員数 | － |
| url | www.benitec.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bntc |
| adr_tso | 2351216 |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 2.45 |
| 時価総額（marketcap） | 5760479.2 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
BNTCのテクニカル分析
BNTCのニュース
Benitec Biopharma Inc.: Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update 2023/05/15 12:01:00 Finanz Nachrichten
HAYWARD, Calif., May 15, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "Company"), a development-stage, gene therapy-focused, biotechnology company developing novel g…
Blustering Stock Grabbing Investor’s Attention: Benitec Biopharma Inc. (NASDAQ:BNTC -12.91%), SciSparc Ltd. (NASDAQ:SPRC -1.36%) 2023/03/09 12:44:30 Stock Equity
Benitec Biopharma Inc. (NASDAQ:BNTC) with the stream of -12.91% also noticed, India SciSparc Ltd. (NASDAQ:SPRC) encountered a rapid change of -1.36% in the last hour of Wednesday’s trading session. On … The post Blustering Stock Grabbing Investor’s Attention: Benitec Biopharma Inc. (NASDAQ:BNTC -12.91%), SciSparc Ltd. (NASDAQ:SPRC -1.36%) appeared first on Stocks Equity .
Traders Recap: Benitec Biopharma Inc. (NASDAQ:BNTC -10.41%), Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ -14.29%) 2023/02/13 17:40:41 Stock Equity
BNTC has seen its SMA50 which is now 20.58%. In looking the SMA 200 we see that the stock has seen a -58.54%. CELZ has seen its SMA50 which is … The post Traders Recap: Benitec Biopharma Inc. (NASDAQ:BNTC -10.41%), Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ -14.29%) appeared first on Stocks Equity .
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday 2023/02/07 12:23:03 InvestorPlace
Source: photo.ua / Shutterstock.com It’s time to start the day with a breakdown of the biggest pre-market stock movers to watch on Tuesday! Moving stocks this morning are earnings reports, a takeover offer, and funding plans. Let’s dive into that news below! Pre-Market Stock Movers: 10 Top Gainers Vaccinex (NASDAQ: VCNX ) stock is rocketing more than 59% alongside heavy pre-market trading. Oak Street Health (NYSE: OSH ) shares are soaring over 35% on reports of a $10.5 billion takeover deal . Celyad Oncology (NASDAQ: CYAD ) stock is surging more than 33% with heavy pre-market trading volume. Myomo (NYSEMKT: MYO ) shares are gaining over 27% after the National Disability Insurance Scheme (NDIS) in Australia approved it . Versus Systems (NASDAQ: VS ) stock is increasing more than 20% after announcing a registered direct offering . SoundHound AI (NASDAQ: SOUN ) shares are climbing over 16% as an AI stock rally continues . LiveOne (NASDAQ: LVO ) stock is rising more than 15% after debtholders exchanged $21 million for shares .
Benitec Biopharma Enrolls First OPMD Subject into the 2023/01/23 14:48:00 businessfortnight.com
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its […] The post Benitec Biopharma Enrolls First OPMD Subject into the appeared first on Businessfortnight .
Blustering Stock Grabbing Investor’s Attention: Benitec Biopharma Inc. (NASDAQ:BNTC -12.91%), SciSparc Ltd. (NASDAQ:SPRC -1.36%) 2023/03/09 12:44:30 Stock Equity
Benitec Biopharma Inc. (NASDAQ:BNTC) with the stream of -12.91% also noticed, India SciSparc Ltd. (NASDAQ:SPRC) encountered a rapid change of -1.36% in the last hour of Wednesday’s trading session. On … The post Blustering Stock Grabbing Investor’s Attention: Benitec Biopharma Inc. (NASDAQ:BNTC -12.91%), SciSparc Ltd. (NASDAQ:SPRC -1.36%) appeared first on Stocks Equity .
Traders Recap: Benitec Biopharma Inc. (NASDAQ:BNTC -10.41%), Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ -14.29%) 2023/02/13 17:40:41 Stock Equity
BNTC has seen its SMA50 which is now 20.58%. In looking the SMA 200 we see that the stock has seen a -58.54%. CELZ has seen its SMA50 which is … The post Traders Recap: Benitec Biopharma Inc. (NASDAQ:BNTC -10.41%), Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ -14.29%) appeared first on Stocks Equity .
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday 2023/02/07 12:23:03 InvestorPlace
Source: photo.ua / Shutterstock.com It’s time to start the day with a breakdown of the biggest pre-market stock movers to watch on Tuesday! Moving stocks this morning are earnings reports, a takeover offer, and funding plans. Let’s dive into that news below! Pre-Market Stock Movers: 10 Top Gainers Vaccinex (NASDAQ: VCNX ) stock is rocketing more than 59% alongside heavy pre-market trading. Oak Street Health (NYSE: OSH ) shares are soaring over 35% on reports of a $10.5 billion takeover deal . Celyad Oncology (NASDAQ: CYAD ) stock is surging more than 33% with heavy pre-market trading volume. Myomo (NYSEMKT: MYO ) shares are gaining over 27% after the National Disability Insurance Scheme (NDIS) in Australia approved it . Versus Systems (NASDAQ: VS ) stock is increasing more than 20% after announcing a registered direct offering . SoundHound AI (NASDAQ: SOUN ) shares are climbing over 16% as an AI stock rally continues . LiveOne (NASDAQ: LVO ) stock is rising more than 15% after debtholders exchanged $21 million for shares .
Benitec Biopharma Enrolls First OPMD Subject into the Clinical Development Program 2023/01/23 14:48:00 GlobeNewswire
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the enrollment of the first oculopharyngeal muscular dystrophy (OPMD) patient into the OPMD natural history phase of the BB-301 clinical development program. The OPMD Natural History (NH) Study represents the 6-month pre-treatment observation period for each OPMD subject prior to the administration of BB-301 for the treatment of OPMD-related dysphagia. Upon the completion of 6-months of radiographic and clinical assessments required for the NH Study, participants will be eligible for enrollment into the BB-301 Phase 1b/2a treatment study in which BB-301 will be administered.
Benitec Biopharma Enrolls First OPMD Subject into the 2023/01/23 14:48:00 businessfortnight.com
HAYWARD, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) — Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “the Company”), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its […] The post Benitec Biopharma Enrolls First OPMD Subject into the appeared first on Businessfortnight .
Benitec Biopharma closes ~$17.9M underwritten public offering 2022/09/16 13:08:02 Seeking Alpha
Gene therapy-focused biotechnology company Benitec Biopharma (BNTC) closed an ~$17.9M underwritten public offering of 29.81M shares and accompanying warrants to purchase up to…
Benitec Biopharma Inc. (NASDAQ: BNTC) Could Post Excellent Profits? 2022/09/14 12:30:00 Marketing Sentinel
In the last trading session, 1.38 million shares of the Benitec Biopharma Inc. (NASDAQ:BNTC) were traded, and its beta was 1.23. Most recently the company’s share price was $0.46, and it changed around -$0.17 or -28.34% from the last close, which brings the market valuation of the company to $4.01M. BNTC currently trades at a … Benitec Biopharma Inc. (NASDAQ: BNTC) Could Post Excellent Profits? Read More »
Benitec Biopharma prices of $18M securities offering 2022/09/13 08:08:53 Seeking Alpha
Benitec Biopharma (BNTC) has priced its underwritten public offering of 29,809,471 shares of its common stock and accompanying warrants to purchase up to 29,809,471 shares of common…
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday''s Mid-Day Session 2022/09/08 16:15:08 Benzinga
Gainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX ) surged 64% to $29.35 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink raised their price targets. Benitec Biopharma Inc. (NASDAQ: BNTC ) shares rose 58% to $0.9346. The company, last week, filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission. Rubius Therapeutics, Inc. (NASDAQ: RUBY ) rose 39.4% to $1.21 after declining 11% on Wednesday. Rubius Therapeutics, last month, posted a Q2 loss of $0.49 per share. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) gained 22.2% to $0.2733. Nutex Health, Inc. (NASDAQ: NUTX ) gained 21.5% to $3.85. Nutex Health recently posted a Q2 loss of $0.03 per share.